MX2023000092A - Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . - Google Patents

Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .

Info

Publication number
MX2023000092A
MX2023000092A MX2023000092A MX2023000092A MX2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A
Authority
MX
Mexico
Prior art keywords
conjugate
relates
saponin
pharmaceutical composition
galnac
Prior art date
Application number
MX2023000092A
Other languages
English (en)
Spanish (es)
Inventor
Ruben Postel
Guy Hermans
Original Assignee
Sapreme Tech Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapreme Tech Bv filed Critical Sapreme Tech Bv
Publication of MX2023000092A publication Critical patent/MX2023000092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
MX2023000092A 2020-06-24 2021-06-18 Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . MX2023000092A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2025899 2020-06-24
NL2026442 2020-09-10
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate

Publications (1)

Publication Number Publication Date
MX2023000092A true MX2023000092A (es) 2023-04-20

Family

ID=76584529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000092A MX2023000092A (es) 2020-06-24 2021-06-18 Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .

Country Status (10)

Country Link
US (1) US20230263897A1 (cg-RX-API-DMAC10.html)
EP (3) EP4171641B1 (cg-RX-API-DMAC10.html)
JP (1) JP2023532040A (cg-RX-API-DMAC10.html)
KR (1) KR20230043114A (cg-RX-API-DMAC10.html)
CN (2) CN116234582A (cg-RX-API-DMAC10.html)
AU (1) AU2026202914A1 (cg-RX-API-DMAC10.html)
ES (1) ES3002193T3 (cg-RX-API-DMAC10.html)
IL (1) IL299357A (cg-RX-API-DMAC10.html)
MX (1) MX2023000092A (cg-RX-API-DMAC10.html)
WO (1) WO2021261992A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072503A (zh) * 2019-07-02 2022-02-18 阿尔戈诺特Rna有限公司 载脂蛋白b拮抗剂
CN117355534B (zh) 2021-01-30 2026-05-01 唐格拉姆治疗公司 缀合寡核苷酸化合物、其制备方法和用途
WO2022162157A1 (en) * 2021-01-30 2022-08-04 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
CN115227700B (zh) * 2022-06-09 2024-03-19 大连医科大学 商陆皂苷甲在制备心肌梗死保护药物中的应用
JP2026519131A (ja) * 2023-06-02 2026-06-11 サプリーム テクノロジーズ,ベー.フェー. 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン
TW202504619A (zh) * 2023-07-20 2025-02-01 大陸商上海舶望製藥有限公司 用於抑制pd-l1表達的組合物和方法
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN116854754B (zh) * 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
WO2025090612A1 (en) * 2023-10-27 2025-05-01 Wisconsin Alumni Research Foundation Lipid nanoparticles formed by lipidoids for efficient delivery of nucleotide drugs and biologics
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275954A1 (en) * 2002-11-08 2004-06-07 Danmarks Fodevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
ES2395818T3 (es) * 2004-07-13 2013-02-15 Charite - Universitatsmedizin Berlin Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
WO2008007941A1 (en) * 2006-07-10 2008-01-17 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Gainac specific binding molecules and uses thereof
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
US20150024037A1 (en) * 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
AR100516A1 (es) * 2014-05-19 2016-10-12 Pfizer Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr
AU2015329974B2 (en) * 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3514240A1 (en) * 2018-01-18 2019-07-24 Freie Universität Berlin Novel uses of a saponin and method for its isolation
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates

Also Published As

Publication number Publication date
IL299357A (en) 2023-02-01
EP4438125A3 (en) 2024-12-25
ES3002193T3 (en) 2025-03-06
CN116234582A (zh) 2023-06-06
JP2023532040A (ja) 2023-07-26
CN120586078A (zh) 2025-09-05
WO2021261992A1 (en) 2021-12-30
KR20230043114A (ko) 2023-03-30
EP4782067A2 (en) 2026-07-29
AU2026202914A1 (en) 2026-05-07
EP4438125A2 (en) 2024-10-02
US20230263897A1 (en) 2023-08-24
EP4171641A1 (en) 2023-05-03
EP4171641B1 (en) 2024-10-30
EP4171641C0 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
EP4438125A3 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
EP4591938A3 (en) Conjugate of saponin, oligonucleotide and galnac
ES2847288T3 (es) Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
Sun et al. Bisphosphonates for delivering drugs to bone
AU2017389094B2 (en) Aptamer-drug conjugate and use thereof
BR112021012222A8 (pt) Molécula de ligação direcionada à célula melhorada
JP2024530839A5 (cg-RX-API-DMAC10.html)
PE20250839A1 (es) Proteinas y conjugados de union al receptor de transferrina
JP2023532040A5 (cg-RX-API-DMAC10.html)
JP2016056209A5 (cg-RX-API-DMAC10.html)
BR112021025394A2 (pt) Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica
EP4529953A3 (en) Conjugate of saponin, oligonucleotide and galnac
US20230173092A1 (en) Antibody-drug conjugates
EP4596052A3 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
MX2022016485A (es) Derivados de saponina con ventana terapeutica mejorada.
CA3121857A1 (en) Antibody-drug conjugates
WO2022194988A3 (en) B-lymphocyte specific amatoxin antibody conjugates
EP3218010B1 (en) Polymer composed of repeat units having a biologically active molecule attached thereto via a ph-sensitive bond
Kwon et al. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation
JP2026502232A (ja) エキサテカン誘導体を含むuPARAPを標的とする抗体薬物複合体
JP2009540842A5 (cg-RX-API-DMAC10.html)
MX2023014899A (es) Nuevos conjugados que comprenden fosfoantígenos y su uso en terapia.
MX2023000031A (es) Conjugado de un anticuerpo de dominio unico, una saponina y una molecula efectora, composicion farmaceutica que comprende el mismo, uso terapeutico de dicha composicion farmaceutica.
CN113164474B (zh) 维奈托克的水溶性高分子衍生物
US20250041439A1 (en) Antibody-drug conjugates